

- Peters J. Breast cancer genetics: relevance to oncology practice. *Cancer Control* 1995;2:195–208.
- Brierley KL, Campfield D, Ducaine W, et al. Errors in delivery of cancer genetics services: implications for practice. *Conn Med* 2010;74:413–423.
- Brierley KL, Blouch E, Cogswell W, et al. Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications. *Cancer J* 2012;18:303–309.
- American College of Surgeons, Commission on Cancer: Cancer Program Standards 2012: Ensuring Patient-Centered Care. <http://www.facs.org/cancer/coc/programstandards2012.html> Accessed on December 3, 2012.
- Yale Cancer Genetic Counseling Program. Mammography techs ordering their own genetic testing? It appears our suspicion was correct. [yalecancer-genetic-counseling.blogspot.com](http://yalecancer-genetic-counseling.blogspot.com) October 2, 2013. <http://yalecancer-genetic-counseling.blogspot.com/2013/10/mammography-techs-ordering-their-own.html>
- Lubin IM, Caggana M, Constantin C, et al. Ordering molecular genetic tests and reporting results: practices in laboratory and clinical settings. *J Mol Diagn* 2008;10:459–468.
- Weeks WB, Wallace AE. Time and money: a retrospective evaluation of the inputs, outputs, efficiency, and incomes of physicians. *Arch Intern Med* 2003;163(8):944–948.
- Doksum T, Bernhardt BA, Holtzman NA. Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing? *Genet Med* 2003;5:99–105.
- Rosenthal ET. Shortage of genetics counselors may be anecdotal, but need is real. *Oncology Times* 2007;29:34–36.
- Informed Medical Decisions. Adult Genetics: Genetic counseling for your health concerns. Available at: <http://www.informedna.com/index.php/patients/adult-genetics.html>. Accessed August 24, 2009.
- Informed Medical Decisions. News: Aetna Press Release: Aetna to offer access to confidential telephonic cancer genetic counseling to health plan members. Available at: [http://www.informedna.com/images/stories/news\\_articles/aetna%20press%20release%20bw.pdf](http://www.informedna.com/images/stories/news_articles/aetna%20press%20release%20bw.pdf). Accessed August 24, 2009.
- Schneider, ME. Cigna to require counseling for some genetic tests. *Internal Medicine News Digital Network*. July 26, 2013. <http://www.internalmedicine.com/single-view/cigna-to-require-counseling-for-some-genetic-tests/efd4f421df8b46ba2208da423adf198d.html>
- Claus E, Schildkraut J, Thompson W, et al. The genetic attributable risks of breast and ovarian cancer. *Cancer* 1996;77:2318–2324.
- Loman N, Johannsson O, Kristofferson U. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. *J Natl Cancer Inst* 2001;93:1215.
- Struewing J, Hartge P, Wacholder S. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med* 1997;336:1401–1408.
- Eisinger F, Jacquemier J, Charpin C, et al. Mutations at BRCA1: the medullary breast carcinoma revisited. *Cancer Res* 1998;58:1588–1592.
- Kandel M, Stadler Z, Masciarri S, et al. Prevalence of BRCA1 mutations in triple negative breast cancer. Paper presented at: 2006 42nd Annual ASCO Meeting; 2006; Atlanta, GA.
- National Comprehensive Cancer Network Clinical Guidelines in Oncology: Genetics/Familial High-Risk Assessment - Breast and Ovarian Cancer. [http://www.nccn.org/professionals/physician\\_gls/f\\_guidelines.asp#detection](http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#detection) Accessed November 2, 2012.
- Risch H, McLaughlin J, Cole D, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. *JNCI* 2006;98:1694–706.
- Matloff E, Brierley K, Chimera C. A clinician's guide to hereditary colon cancer. *Cancer J* 2004;10(5):280–287.
- Pilarski R. Cowden syndrome: a critical review of the clinical literature. *J Genet Couns* 2009 Feb;18:13–27.
- Varga EA, Pastore M, Prior T, et al. The prevalence of PTEN mutations in a clinical pediatric cohort with autism spectrum disorders, developmental delay, and macrocephaly. *Genet Med* 2009;11:111–117.
- Corlin R. Nevoid basal-cell carcinoma syndrome. *Medicine* 1987;66(2):98–113.
- Schneider K. *Counseling About Cancer: Strategies for Genetic Counseling*. 2nd ed. Wiley-Liss; 2001.
- Love R, Evan A, Josten D. The accuracy of patient reports of a family history. *J Chronic Dis* 1985;38(4):289–293.
- Alter B, Rosenberg P, Brody L. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. *J Med Genet* 2007;44:1–9.
- Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. *J Natl Cancer Inst* 2005;97:813–822.
- Korzenik J, Chung D, Digumarthy S, et al. Case 33-2005: a 43 year-old man with lower gastrointestinal bleeding. *N Engl J Med* 2005;353:1836–1844.
- American Cancer Society. *Cancer Facts and Figures 2009*. Atlanta, GA: American Cancer Society; 2009.
- Olopade O, Weber B. Breast cancer genetics: toward molecular characterization of individuals at increased risk for breast cancer. Part II. PPO Updates 1998;12:1–8.
- Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. *Nat Genet* 2008;40:17–22.
- Gail M, Brinton L, Byar D. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. *J Natl Cancer Inst* 1989;81:1879–1886.
- Claus E, Risch N, Thompson W. Autosomal dominant inheritance of early-onset breast cancer. *Cancer* 1994;73:643.
- Parmigiani G, Berry D, Aguiar O. Determining carrier probabilities for breast cancer susceptibility genes BRCA1 and BRCA2. *Am J Hum Genet* 1998;62:145–158.
- Friedman S. *Thoughts from FORCE: Comments Submitted to the Secretary's Advisory Committee on Genetics Health and Society*. <http://facingourrisk.wordpress.com/2008/12/03/comments-submitted-to-the-secretarys-advisory-committee-on-genetics-health-and-society/>. Accessed April 6, 2010.
- UnitedHealth. *Personalized Medicine: Trends and Prospects for the New Science of Genetic Testing and Molecular Diagnostics*. Working Paper 7. Minnetonka, MN: UnitedHealth Center for Health Reform & Modernization; March 2012.
- ARUP Laboratories. *Value of Genetic Counselors in the Laboratory*. Salt Lake City: ARUP Laboratories; March 2011.
- Plon SE, Cooper HP, Parks B, et al. Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. *Genet Med* 2011;13:148–154.
- Walsh T. *More Than 25% of Breast Cancer Families with Wild-Type Results from Commercial Genetic Testing of BRCA1 and BRCA2 Are Resolved by BROCA Sequencing of All Known Breast Cancer Genes*. Paper presented at: 2013 American Society of Human Genetics Meeting Session #19; 2013; Boston, MA.
- U.S. Preventive Services Task Force. *Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility*. Rockville, MD: Agency for Healthcare Research and Quality; 2013. <http://www.uspreventiveservicestaskforce.org/uspstf12/brcatest/brcatestfinalrs.htm>. Accessed June 2, 2014.
- King MC, Marks JH, Mandell JB, et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. *Science* 2003;302:643–646.
- Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 2003;72:1117–1130.
- Ford D, Easton D, Bishop D, et al. Risks of cancer in BRCA1 mutation carriers. *Lancet* 1994;343:692–695.
- Piver M, Jishi M, Tsukada Y. Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. *Cancer* 1993;71:2751–2755.
- Aziz S, Kuperstein G, Rosen B. A genetic epidemiological study of carcinoma of the fallopian tube. *Gynecol Oncol* 2001;80:341–345.
- van Asperen C, Brohet R, Meijers-Heijboer, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. *J Med Genet* 2005;42:711–719.
- Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. *J Natl Cancer Inst* 1999;91:1310–1316.
- Warner E, Plewes D, Hill K, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. *JAMA* 2004;292:1317–1325.
- Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. *N Engl J Med* 2004;29:351:427–437.
- Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA Trial. *J Clin Oncol* 2010;1450–1457.
- Powles T, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. *J Natl Cancer Inst* 2007;99:283–290.
- Cuzick J, Forbes J, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer: 96 month follow-up of the randomized IBIS-I trial. *J Natl Cancer Inst* 2007;99:272–282.
- Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. *N Engl J Med* 2011;364:2381.
- Fisher B, Constantino J, Wickerman D. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J Natl Cancer Inst* 1998;90:1371–1388.
- King M, Wieand S, Hale K. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. *JAMA* 2001;286:2251–2256.
- Narod S, Brunet J, Ghadirian P. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. *Lancet* 2000;356:1876–1881.
- Phillips KA, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *J Clin Oncol* 2013;31:3091–3099.
- Lakhani S, van de Vijver M, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. *J Clin Oncol* 2002;20:2310–2318.

59. Hartmann L, Schaid D, Woods J. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. *N Engl J Med* 1999;340:77–84.
60. Matloff E. The breast surgeon's role in BRCA1 and BRCA2 testing. *Am J Surg* 2000;180:294–298.
61. Turner B, Harold E, Matloff E, et al. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: Implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. *J Clin Oncol* 1999;17:3017–3024.
62. Contant CM, et al. Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HBOC) or a proven BRCA1 or BRCA2 germ-line mutation. *Eur J Surg Oncol* 2002;28:627–632.
63. Forman DL, Chiu J, Restifo RJ, et al. Breast reconstruction in previously irradiated patients using tissue expanders and implants: a potentially unfavorable result. *Ann Plast Surg* 1998;40:360–363.
64. McLaughlin J, Risch H, Lubinski J, et al. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. *Lancet* 2007;8:26–34.
65. Milne R, Knight J, John E, et al. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. *Cancer Epidemiol Biomarkers Prev* 2005;14:350–356.
66. Domchek S, Friebel T, Neuhausen S, et al. Mortality reduction after risk-reducing bilateral salpingo-oophorectomy in a prospective cohort of BRCA1 and BRCA2 mutation carriers. *Lancet Oncol* 2006;7:223–229.
67. Powel CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. *J Clin Oncol* 2005;23:127–132.
68. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. *JAMA* 2006;296:185–192.
69. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. *J Clin Oncol* 2010;28:222–231.
70. Kwon JS, Tinker A, Pansegrau G, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. *Obstet Gynecol* 2013;121:14–24.
71. American College of Obstetricians and Gynecologists. ACOG committee opinion. Breast-ovarian cancer screening. Number 176, October 1996. Committee on Genetics. The American College of Obstetricians and Gynecologists. *Int J Gynaecol Obstet* 1997;56:82–83.
72. Hornreich G, Beller U, Lavie O. Is uterine serous papillary carcinoma a BRCA1 related disease? Case report and review of the literature. *Gynecol Oncol* 1999;75(2):300–304.
73. Levine D, Lin P, Barakat R. Risk of endometrial carcinoma associated with BRCA mutation. *Gynecol Oncol* 2001;80(3):395–398.
74. Goshen R, Chu W, Eli L. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? *Gynecol Oncol* 2000;79(3):477–481.
75. Boyd J. The breast, ovarian, and other cancer genes. *Gynecol Oncol* 2001;80(3):337–340.
76. Campfield Bonadies D, Moyer A, Matloff ET. What I wish I'd known before surgery: BRCA carriers' perspectives after bilateral salpingo-oophorectomy. *Fam Cancer* 2011;10:79–85.
77. Rebbeck T, Lynch H, Neuhausen S, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. *N Engl J Med* 2002;346:1616–1622.
78. Kauff N, Satagopan J, Robson M, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 2002;346:1609–1615.
79. Rebbeck T, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group. *J Clin Oncol* 2005;23:7804–7810.
80. Gronwald J, Tung N, Foulkes W, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. *Int J Cancer* 2006;118:2281–2284.
81. Fong PC, Boss DS, Yap TA, et al. Inhibition of Poly (ADPRibose) Polymerase in Tumors from BRCA Mutation Carriers. *N Engl J Med* 2009;361:1–12.
82. Ingelhart JD, Silver DP. Synthetic lethality – a new direction in cancer-drug development. *N Engl J Med* 2009;361:1–3.
83. Kash K, Holland J, Halper M, et al. Psychological distress and surveillance behaviors of women with a family history of breast cancer. *J Natl Cancer Inst* 1992;84:24–30.
84. Lerman C, Hughes C, Lemon S. What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. *J Clin Oncol* 1998;16:1650–1654.
85. Croyle R, Smith K, Botkin J. Psychological responses to BRCA1 mutation testing: preliminary findings. *Health Psychol* 1997;16:63–72.
86. Hamilton JG, Lobel M, Moyer A. Emotional distress following genetic testing for hereditary breast and ovarian cancer: a meta-analytic review. *Health Psychol* 2009;28:510–518.
87. Clayton E. Removing the shadow of the law from the debate about genetic testing of children. *Am J Med Genet* 1995;57:630–634.
88. ASHG/ACMG. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. *Am J Hum Genet* 1995;57:1233–1241.
89. Ledger G, Khosia S, Lindor N, et al. Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II. *Ann Intern Med* 1995;122:118–124.
90. Rhodes M, Bradburn D. Overview of screening and management of familial adenomatous polyposis. *Br J Surg* 1992;33:125–123.
91. Howard HC, Avar D, Borry P. Are the kids really all right? Direct-to-consumer genetic testing in children: are company policies clashing with professional norms? *Eur J Hum Genet* 2011;19:1122–1126.
92. Tsoucalas C. Legal aspects of cancer genetics - screening, counseling, and registers. In: Lynch H, Kullander S, eds. *Cancer Genetics in Women*. Vol I. Boca Raton, FL: CRC Press, Inc.; 1987:9.
93. American Society of Human Genetics. ASHG Statement: professional disclosure of familial genetic information. *Am J Hum Genet* 1998;62:474–483.
94. Bluman L, Rimer B, Berry D. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. *J Clin Oncol* 1999;17:1040–1046.
95. Matloff E, Shappell H, Brierley K, et al. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery and insurance discrimination. *J Clin Oncol* 2000;18:2484–2492.
96. Hall MA, Rich SS. Patients' fear of genetic discrimination by health insurers: the impact of legal protections. *Genet Med* 2000;2:214–221.
97. Leib JR, Hoodfar E, Larsen Haidle J, Nagy R. The new genetic privacy law. *Community Oncol* 2008;5:351–354.
98. Hudson KL, Holohan JD, Collins FS. Keeping pace with the times — the Genetic Information Nondiscrimination Act of 2008. *N Engl J Med* 2008;358:2661–2663.
99. The Genetic Information Nondiscrimination Act of 2008 (H.R. 493). Library of Congress Web site. <http://beta.congress.gov/bill/110th-congress/house-bill/493>. Accessed June 2, 2014.
100. The Health Care and Education Affordability Reconciliation Act of 2010 (H.R. 4872). Library of Congress Web site. <http://beta.congress.gov/bill/111th-congress/house-bill/4872>. Accessed June 2, 2014.
101. Manley S, Pennell R, Frank T. Insurance coverage of BRCA1 and BRCA2 sequence analysis. *J Genet Couns* 1998;7:A462.
102. Grann V, Whang W, Jabcobson J, et al. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. *J Clin Oncol* 1999;17:494–500.
103. Offit K, Kohut K, Clagett B, et al. Cancer genetic testing and assisted reproduction. *J Clin Oncol* 2006;24:4775–4782.
104. Offit K, Levan O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. *J Natl Cancer Inst* 2003;95(20):1548–1551.
105. Greendale K, Pyeritz RE. Empowering primary care health professionals in medical genetics: How soon? How fast? How far? *Am J Med Genet* 2001;106:223–232.
106. Wilkins-Haug L, Hill LD, Power ML, et al. Gynecologists' training, knowledge, and experiences in genetics: a survey. *Obstet Gynecol* 2000;95:421–424.
107. Wood ME, Stockdale A, Flynn BS. Interviews with primary care physicians regarding taking and interpreting the cancer family history. *Fam Pract* 2008;25:334–340.
108. Bellcross CA, Kolor K, Goddard K, et al. Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. *Am J Prev Med* 2011;40:61–66.
109. Pollack A. F.D.A. Orders genetic testing firm to stop selling DNA analysis service. *New York Times*. November 25, 2013. [http://www.nytimes.com/2013/11/26/business/fda-demands-a-halt-to-a-dna-test-kits-marketing.html?\\_r=0](http://www.nytimes.com/2013/11/26/business/fda-demands-a-halt-to-a-dna-test-kits-marketing.html?_r=0)